Wednesday, July 8, 2026

Patent directory · USPTO A61K / A61P

Patents matching “VACCINEX, INC.”

41 pharma patents match "VACCINEX, INC." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 41
Index total 30,257
Page 1 / 2

Quick answer

This filtered view shows 41 pharmaceutical patents matching "VACCINEX, INC." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

41 results for “VACCINEX, INC.” · 30,257 patents in full index Clear search

  1. US 12201719

    Combination therapy with semaphorin-4D blockade (SEMA4D) and DC1 therapy

    VACCINEX, INC. · Granted Jan 21, 2025 · Expires Jan 16, 2045

    granted
  2. US 12070500

    Use of semaphorin-4D antibodies in combination with an immune modulating therapy to inhibit tumor growth and metastasis

    VACCINEX, INC. · Granted Aug 27, 2024 · Expires Aug 22, 2044

    granted
  3. US 12006365

    Human anti-semaphorin 4D antibody

    VACCINEX, INC. · Granted Jun 11, 2024 · Expires Jun 6, 2044

    granted
  4. US 12006364

    Anti-CD100 antibodies and methods for using the same

    VACCINEX, INC. · Granted Jun 11, 2024 · Expires Jun 6, 2044

    granted
  5. US 11981730

    Anti-CXCL13 antibodies and methods of using the same

    VACCINEX, INC. · Granted May 14, 2024 · Expires May 9, 2044

    granted
  6. US 11859000

    Anti-CCR8 antibodies and uses thereof

    VACCINEX, INC. · Granted Jan 2, 2024 · Expires Dec 28, 2043

    granted
  7. US 11660330

    Combination therapy with semaphorin-4D blockade (SEMA4D) and DC1 therapy

    VACCINEX, INC. · Granted May 30, 2023 · Expires May 25, 2043

    granted
  8. US 11597765

    Use of semaphorin-4D binding molecules for the treatment of Rett syndrome

    VACCINEX, INC. · Granted Mar 7, 2023 · Expires Mar 2, 2043

    granted
  9. US 11572408

    Treatment of cancer with a semaphorin-4D antibody in combination with an epigenetic modulating agent

    VACCINEX, INC. · Granted Feb 7, 2023 · Expires Feb 2, 2043

    granted
  10. US 11534488

    Use of semaphorin-4D binding molecules for modulation of blood brain barrier permeability

    VACCINEX, INC. · Granted Dec 27, 2022 · Expires Dec 22, 2042

    granted
  11. US 11427634

    Human anti-semaphorin 4D antibody

    VACCINEX, INC. · Granted Aug 30, 2022 · Expires Aug 25, 2042

    granted
  12. US 11274149

    Anti-CD100 antibodies and methods for using the same

    VACCINEX, INC. · Granted Mar 15, 2022 · Expires Mar 10, 2042

    granted
  13. US 11078295

    Use of semaphorin-4D inhibitory molecules with an immune modulating therapy to inhibit tumor growth and metastases

    VACCINEX, INC. · Granted Aug 3, 2021 · Expires Jul 29, 2041

    granted
  14. US 10829550

    Polynucleotides encoding anti-CXCL13 antibodies

    VACCINEX, INC. · Granted Nov 10, 2020 · Expires Nov 5, 2040

    granted
  15. US 10800853

    Use of semaphorin-4D binding molecules for treating neurodegenerative disorders

    VACCINEX, INC. · Granted Oct 13, 2020 · Expires Oct 8, 2040

    granted
  16. US 10526414

    Use of anti-semaphorin-4D antibodies in combination with an immune modulating therapy to inhibit tumor growth and metastases

    VACCINEX, INC. · Granted Jan 7, 2020 · Expires Jan 2, 2040

    granted
  17. US 10494440

    Use of semaphorin-4D binding molecules to promote neurogenesis following stroke

    VACCINEX, INC. · Granted Dec 3, 2019 · Expires Nov 28, 2039

    granted
  18. US 10385136

    Use of semaphorin-4D binding molecules for treating neurodegenerative disorders

    VACCINEX, INC. · Granted Aug 20, 2019 · Expires Aug 15, 2039

    granted
  19. US 10301393

    Methods of treating multiple sclerosis using anti-CD20 antibodies

    VACCINEX, INC. · Granted May 28, 2019 · Expires May 23, 2039

    granted
  20. US 10111950

    Modified glycolipids and methods of making and using the same

    VACCINEX, INC. · Granted Oct 30, 2018 · Expires Oct 25, 2038

    granted
  21. US 9963504

    Anti-CXCL13 antibodies and methods of using the same

    VACCINEX, INC. · Granted May 8, 2018 · Expires May 3, 2038

    granted
  22. US 9890213

    Methods for the treatment of B cell-mediated inflammatory diseases

    VACCINEX, INC. · Granted Feb 13, 2018 · Expires Feb 8, 2038

    granted
  23. US 9828435

    Use of antibodies or antigen-binding fragments thereof that specifically bind semaphorin-4D to increase tumor infiltrating leukocyte frequency

    VACCINEX, INC. · Granted Nov 28, 2017 · Expires Nov 23, 2037

    granted
  24. US 9790271

    Methods for increasing immunoglobulin A levels

    VACCINEX, INC. · Granted Oct 17, 2017 · Expires Oct 12, 2037

    granted